Hematology

Welcome to your home for all things Mayo Clinic Hematology. At Mayo Clinic, hematologists work in collaboration with teams of experts from virtually every medical and surgical specialty for the care of adults and children with blood diseases, including various cancers of the blood and bone marrow.

Follow the Hematology page and stay up-to-date as we post stories, clinical trials, resources, and useful information regarding your hematological diagnosis. Post a comment and share your thoughts.

PUBLIC PAGE
Wed, Dec 20, 2017 9:53am

International research team identifies genetic-based model for predicting outcomes in primary Myelofibrosis

By Mayo Clinic Hematology Staff, @mayoclinichematologystaff

Myelofibrosis-of-the-bone-marrow-with-replacement-of-normal-marrow-by-fibrous-connective-tissue_shutterstock_167372354

Original post by Joe Dangor in the News Network

A group of investigators from Mayo Clinic and multiple academic research centers in Italy have identified a genetic model for predicting outcomes in patients with primary myelofibrosis who are 70 years or younger and candidates for stem cell transplant to treat their disease. The group’s findings were presented today at the 59th American Society of Hematology annual meeting in Atlanta by lead authors Alessandro Vannucchi, M.D. from the University of Florence and Ayalew Tefferi, M.D., a hematologist at Mayo Clinic.

“Myelofibrosis is a rare type of chronic leukemia that disrupts the body's normal production of blood cells,” says Dr. Tefferi. “Prior to this study, the most comprehensive predictive model for outcomes in myelofibrosis, utilized mostly clinical variables, such as age, hemoglobin level, symptoms, white blood cell count and the percentage of immature cells in the peripheral blood.”

Dr. Tefferi says he and his colleagues incorporated new genetic tests in the model for gene mutations including JAK2CALR, and MPL, which are known to drive myelofibrosis. He says the new model also tests for the presence or absence of high-risk mutations such as ASXL1 and SRSF2. “Our model is also unique in that we developed it for patients who are age 70 years or younger who may still be candidates for a stem cell transplant to treat their disease,” Dr. Tefferi says.

Researchers studied 805 patients with primary myelofibrosis who were 70 years of age or younger. Patients were recruited from multiple centers in Italy and from Mayo Clinic in Minnesota. The Italian and Minnesota groups formed two independent learning and validation cohorts. “We were surprised by how similar the predictive models performed in two completely separate patient databases,” Dr. Tefferi says.

Dr. Tefferi says that genetic information is increasingly being used as a prognostic biomarker in patients with primary myelofibrosis and he anticipates the potential use of such an approach along with relevant clinical, cytogenetic and mutational data for other hematologic and non-hematologic cancers.

 

Want to continue the discussion with Connect members who also live with this condition? Join the following conversations:

Please login or register to post a reply.

Invite Others

Send an email to invite people you know to join the Hematology page.

We'll include this text in the user's invitation.